Company Overview and News


Add SGYP
to your dashboard

Headline News

An Overview of Trulance: Synergy Pharmaceuticals’ First Commercialized Drug

23h marketrealist
Since its launch, Synergy Pharmaceuticals’ (SGYP) Trulance sales have been steadily rising. According to Synergy, in 3Q17, more than 25,000 prescriptions were filled for the drug, representing a 105% rise over prescription fills in 2Q17. A total of nearly 38,000 prescriptions have been filled since the launch of Trulance in March 2017. (244-1)

Inside Synergy Pharmaceuticals: Your Investor Overview

2017-11-21 marketrealist
Synergy Pharmaceuticals (SGYP) is a biopharmaceutical company focused on developing drugs for GI (gastrointestinal) diseases like CIC (chronic idiopathic constipation), IBS-C (irritable bowel syndrome with constipation), and opioid-induced constipation and ulcerative colitis. According to Synergy, it’s estimated that ~33 million people suffer from CIC and 12 million people suffer from IBS-C in the US. (240-0)

Synergy Pharmaceuticals: What Will It Take To Rebound?

2017-11-21 seekingalpha
The need for a new capital raise became evident upon inspection of the company’s latest SEC filing, though it was poorly highlighted by management. (240-1)

Synergy Pharmaceuticals: Dissecting 3rd Quarter Cash Flow And Looking Forward

2017-11-18 seekingalpha
They had about $118 million in cash at 9/30/2017, plus net proceeds about $53 million from the recent equity offering. (240-2)

Tracking John Paulson's Paulson & Company Portfolio - Q3 2017 Update

2017-11-18 seekingalpha
Paulson & Company's largest three positions are the SPDR Gold ETF, Shire plc, and Mylan NV. (1155-8)

Synergy Pharmaceuticals: Balancing Trust With Value

2017-11-17 seekingalpha
Due to a loan which only disburses itself in tranches if Synergy jumps difficult hurdles, further dilution, baring some event, seems likely. (240-0)

Is Synergy Pharmaceuticals A Buy?

2017-11-16 seekingalpha
On November 13th, Synergy announced a financing priced below market with a full warrant that surprised investors. (240-3)

Synergy Pharmaceuticals: How To Destroy Shareholder Value

2017-11-15 seekingalpha
It takes more than have a successful best of breed drug and beating quarterly estimates to succeed in the small biopharma space. (327-2)

Your Daily Pharma Scoop: Portola Ahead Of Catalysts, AstraZeneca Gets 2 FDA Approvals, GW Pharmaceuticals' Price Target Lowered

2017-11-15 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (1487-9)

Your Daily Pharma Scoop: Portola Ahead Of Catalysts, AstraZeneca Gets Two FDA Approvals, GW Pharmaceuticals' Price Target Lowered

2017-11-15 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (1487-2)

Kinder Morgan, AK Steel Tumble into Wednesday’s 52-Week Low Club

2017-11-15 247wallst
November 15, 2017: Here are four stocks trading with heavy volume among 179 equities making new 52-week lows in Wednesday’s session. On the NYSE decliners led advancers by about 3 to 2 and on the Nasdaq, decliners led advancers by roughly the same ratio. (287-0)

Synergy - $300 Million Loan Agreement September 1, $56 Million Secondary November 13, What Happened?

2017-11-15 seekingalpha
Synergy announced a $300 million debt financing on September 1, 2017, addressing (we thought) liquidity and dilution issues. (236-3)

General Electric, Synergy Pharma Stuck Again in Tuesday’s 52-Week Low Club

2017-11-14 247wallst
November 14, 2017: Here are four stocks trading with heavy volume among 170 equities making new 52-week lows in Tuesday’s session. On the NYSE decliners led advancers by about 3 to 2 and on the Nasdaq, decliners and advancers by less than 4 to 3. (333-3)

Synergy Pharmaceuticals: A Misjudged Secondary Offering

2017-11-14 seekingalpha
Synergy announced Monday that it would raise $56 million in a secondary offering; the market reacted poorly to news. (240-5)

General Electric, LendingClub Fall into Monday’s 52-Week Low Club

2017-11-13 247wallst
November 13, 2017: Here are four stocks trading with heavy volume among 146 equities making new 52-week lows in Monday’s session. On the NYSE decliners led advancers by around 8 to 7 and on the Nasdaq, decliners and advancers closed roughly even. (264-4)

Stock Research Report

Synergy Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies. The company has pioneered discovery, research and development efforts around analogs of uroguanylin, a naturally occurring and endogenous human GI peptide, for the treatment of GI diseases and disorders. The company discovered, are developing and control 100% worldwide rights to its proprietary uroguanylin based GI platform, which includes one commercial product, TRULANCE (plecanatide), and a second product candidate, dolcanatide.

TRULANCE (plecanatide)

Its first and only commercial product, TRULANCE™, is approved and marketed in the United States (U.S.), under the trademark name TRULANCE™, as a once-daily treatment for adults with chronic idiopathic constipation, or CIC. In clinical trials, TRULANCE helped improve stool consistency and provide more regular bowel movements. TRULANCE is the only prescription medication for CIC that c...

Click for full article
CUSIP: 871639308